These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature]. Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442 [TBL] [Abstract][Full Text] [Related]
7. Update on the treatment of multiple myeloma. Kyle RA Oncologist; 2001; 6(2):119-24. PubMed ID: 11306723 [TBL] [Abstract][Full Text] [Related]
8. Treatment of multiple myeloma. San Miguel JF; Bladé Creixenti J; García-Sanz R Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392 [TBL] [Abstract][Full Text] [Related]
9. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574 [TBL] [Abstract][Full Text] [Related]
10. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361 [TBL] [Abstract][Full Text] [Related]
11. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697 [TBL] [Abstract][Full Text] [Related]
12. [High-dose melphalan with stem cell support is now an established myeloma therapy. Treatment of myeloma from a 30-year perspective]. Hjorth M; Lenhoff S; Turesson I; Westin J Lakartidningen; 2000 Oct; 97(41):4585-6, 4589-92. PubMed ID: 11107744 [TBL] [Abstract][Full Text] [Related]
13. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs. Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912 [TBL] [Abstract][Full Text] [Related]
14. Treatment of myeloma. Smith ML; Newland AC QJM; 1999 Jan; 92(1):11-4. PubMed ID: 10209667 [TBL] [Abstract][Full Text] [Related]
15. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy. Kyle RA Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780 [TBL] [Abstract][Full Text] [Related]
16. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma. Huijgens PC; Dekker-Van Roessel HM; Jonkhoff AR; Admiraal GC; Zweegman S; Schuurhuis GJ; Ossenkoppele GJ Bone Marrow Transplant; 2001 May; 27(9):925-31. PubMed ID: 11436102 [TBL] [Abstract][Full Text] [Related]
17. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. Vesole DH; Crowley JJ; Catchatourian R; Stiff PJ; Johnson DB; Cromer J; Salmon SE; Barlogie B J Clin Oncol; 1999 Jul; 17(7):2173-9. PubMed ID: 10561273 [TBL] [Abstract][Full Text] [Related]
18. Haematopoietic stem-cell transplantation in multiple myeloma. Handelsman H Cancer Treat Rev; 1996 Mar; 22(2):119-25. PubMed ID: 8665564 [No Abstract] [Full Text] [Related]
19. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol]. Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962 [TBL] [Abstract][Full Text] [Related]